Advertisement

Rheumatology International

, Volume 39, Issue 6, pp 1019–1025 | Cite as

Power-Doppler perfusion phenotype in RA patients is dependent on anti-citrullinated peptide antibody status, not on rheumatoid factor

  • O. GadeholtEmail author
  • M. Feuchtenberger
  • T. Wech
  • E. C. Schwaneck
Observational Research

Abstract

It is not known whether there are any consistent non-serological differences between seropositive and seronegative rheumatoid arthritis, and if any, whether they depend upon rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA), or both. In a pilot study, we showed that the two forms could be differentiated using power-Doppler sonography (PDS), and that the difference is ACPA dependent. This extended study explored whether the previous findings could be confirmed. 103 patients 51 ACPA positive (ACPA +), 52 ACPA negative (ACPA −) with active wrist arthritis were examined using PDS. By means of a temporal image series, pulsatility was evaluated over a 3–5-s period, maximum and minimum perfusion signal were determined using a computer program counting the number of coloured pixels for each frame. Maxima (Pmax) and minima (Pmin) were determined, and the standardized peak-to-peak amplitude sA was calculated (sA = (Pmax − Pmin)/Pmax). This parameter was then compared for ACPA + and ACPA- patients. In addition, a multivariate regression was performed, to determine which factors influence sA. sA differed significantly between ACPA + and ACPA- patients [20% (13–26) vs. 41% (32–57), p < 0. 0001]. In the multivariate analysis, age (t = 2.5, p = 0.02) and ACPA status (t = − 4.8, p < 0.0001) were independent predictors of sA. PDS perfusion patterns are different in seropositive and seronegative RA. The difference appears to be ACPA, not RF dependent. This suggests that the underlying pathophysiological process is different in ACPA-positive and ACPA-negative RA.

Keywords

Power-Doppler sonography ACPA-negative RA Perfusion pattern 

Notes

Acknowledgements

The authors would like to thank Hans-Peter Tony MD, PhD for his input in drafting the manuscript, and Tobias Müller for assistance with performing the multivariate regression. No external writers were involved in manuscript drafting or preparation.

Author contributions

OG: underlying observation, study design, patient recruitment, sonographic examination, data analysis, data interpretation, and first draft; MF: patient recruitment, sonographic examination, and draft revision; TW: data preparation, data post-processing, and draft revision; ECS: study design, patient recruitment, sonographic examination, data interpretation, and draft revision.

Funding

No external funding was obtained for performing this study.

Compliance with ethical standards

Conflict of interest

OG: speaker’s fees from Abbvie, Chugai, Janssen-Cilag, Novartis, and Sanofi. Grants from Abbvie, Chugai, Janssen-Cilag, Lilly, Novartis and Roche. Advisory board participation for Novartis. All outside the submitted work. MF: personal Fees from Abbvie, Chugai, Janssen-Cilag MSD, Pfizer, Roche and UCB. All outside the submitted work. TW: research grant from Siemens Healthcare. Outside the submitted work. ECS: speaker’s fees from Abbvie, Chugai, Jansen-Cilag, Lilly, Novartis and Shire. Grants from Abbvie, Celgene, Chugai, Novartis and Shire. All outside the submitted work.

Ethics approval

Final approval by the ethics committee of the University of Würzburg, Würzburg, Germany 20.07.2018 (Protocol Number 22/18). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Data sharing

No application was submitted to the ethics commission of the University of Würzburg for permission to share the obtained data. Hence, the data cannot be made available for further analysis.

Supplementary material

296_2019_4256_MOESM1_ESM.avi (706 kb)
Supplementary material 1 (AVI 706 KB)
296_2019_4256_MOESM2_ESM.avi (995 kb)
Supplementary material 2 (AVI 995 KB)

References

  1. 1.
    Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, Smolen J, Yazici H (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:34–45CrossRefPubMedGoogle Scholar
  2. 2.
    Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74:2151–2156CrossRefPubMedGoogle Scholar
  3. 3.
    Pratt AG, Isaacs JD (2014 Aug) Seronegative rheumatoid arthritis: pathogenic and therapeutic aspects. Best Pract Res Clin Rheumatol 28(4):651–659CrossRefPubMedGoogle Scholar
  4. 4.
    Harris ED Jr, Firestein GS (2009) Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS (eds) Kelley’s textbook of rheumatology, 8th edn. Elsevier, PhiladelphiaGoogle Scholar
  5. 5.
    Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, Williams S, Lal P, Read SJ (2013) Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 72(3):329–336CrossRefPubMedGoogle Scholar
  6. 6.
    Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh (2016) A brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis. Arthritis Rheumatol 68(6):1346–1352CrossRefPubMedGoogle Scholar
  7. 7.
    Padyukov L, Seielstad M, Ong RT, Ding B, Rönnelid J, Seddighzadeh M, Alfredsson L, Klareskog L (2011) Epidemiological investigation of rheumatoid arthritis (EIRA) study group: a genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70:259–265CrossRefPubMedGoogle Scholar
  8. 8.
    Gadeholt O (2017) Rheumatoid arthritis is not a single disease. Clin Exp Rheumatol 35(Suppl 104(2):20–21PubMedGoogle Scholar
  9. 9.
    De Rooy DP, Willemze A, Mertens B, Huizinga TWJ van der (2011) Helm-van Mil AHM: can anti-cyclic citrullinated peptide antibody-negative RA be subdivided into clinical subphenotypes? Arthritis Res Ther 13:R180CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Turkcapar N, Demir O, Atli T, Kopuk M, Turgay M, Kinikli G, Duman M (2006) Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr 42(2):225–231CrossRefPubMedGoogle Scholar
  11. 11.
    Burgers LE, van Steenbergen HW, ten Brinck RM, Huizinga TW van der (2017) Helm-van Mil AH: Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Ann Rheum Dis 76:1751–1754CrossRefPubMedGoogle Scholar
  12. 12.
    Burns TM, Calin A (1983) The hand radiograph as a diagnostic discriminant between seropositive and seronegative ‘rheumatoid arthritis’: a controlled study. Ann Rheum Dis 42:605–612CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRefGoogle Scholar
  14. 14.
    Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42(5):677–680CrossRefPubMedGoogle Scholar
  15. 15.
    Hecht C, Schett G, Finzel S (2015) The impact of rheumatoid factor and ACPA on bone erosion in rheumatoid arthritis. Ann Rheum Dis 74(1):e4CrossRefPubMedGoogle Scholar
  16. 16.
    Gadeholt O, Wech T, Schuh S, Scharbatke EC, Ostermeier E, Tony HP, Schmalzing M (2016) Anti-CCP status determines the power Doppler oscillation pattern in rheumatoid arthritis: a prospective study. Rheumatol Int 36:1671–1675CrossRefPubMedGoogle Scholar
  17. 17.
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefGoogle Scholar
  18. 18.
    D’Agostino M-A, Terslev L, Aegerter P, Backhaus M, Balint P, Bruyn GA, Filippucci E, Grassi W, Iagnocco A, Jousse-Jolin S, Kane D, Naredo E, Schmidt W, Szkudlarek M, Conaghan PG, Wakefield RJ (2017) Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce—part 1: definition and development of a standardised, consensus-based scoring system. RMD Open 11(1):e000428 3(CrossRefGoogle Scholar
  19. 19.
    Ragan C (1961) The history of the rheumatoid factor. Arthritis Rheum 4:571–573CrossRefPubMedGoogle Scholar
  20. 20.
    Litwin SD, Singer JM (1965) Studies of the incidence and significance of anti-gamma globulin factors in the aging. Arthritis Rheum 8:538–550CrossRefPubMedGoogle Scholar
  21. 21.
    Boeters D, Gaujoux-Viala C, Constantin A, van der Helm-van Mil AHM (2017) The 2010 ACR/EULAR criteria are not sufficiently accurate in the early identification of autoantibody-negative rheumatoid arthritis: Results from the Leiden-EAC and ESPOIR cohorts. Semin Arthritis Rheum 47(2):170–174CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Rheumatology, Medical Clinic IIUniversity Clinic WürzburgWürzburgGermany
  2. 2.Rheumatologische Schwerpunktpraxis WürzburgWürzburgGermany
  3. 3.Med I Bayern OstBurghausenGermany
  4. 4.Department of Experimental RadiologyUniversity Clinic WürzburgWürzburgGermany

Personalised recommendations